{
  "denotations": [
    {
      "id": "T2",
      "obj": "Disease",
      "span": {
        "begin": 136,
        "end": 153
      }
    },
    {
      "id": "T3",
      "obj": "Chemical",
      "span": {
        "begin": 275,
        "end": 286
      }
    },
    {
      "id": "T4",
      "obj": "Chemical",
      "span": {
        "begin": 299,
        "end": 307
      }
    },
    {
      "id": "T5",
      "obj": "Chemical",
      "span": {
        "begin": 321,
        "end": 330
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 343,
        "end": 351
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 368,
        "end": 390
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 174,
        "end": 184
      }
    },
    {
      "id": "T9",
      "obj": "Chemical",
      "span": {
        "begin": 187,
        "end": 220
      }
    },
    {
      "id": "T11",
      "obj": "Chemical",
      "span": {
        "begin": 226,
        "end": 246
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "22102708_4",
  "text": "DESIGN AND METHODS : We compared the clinical and hematologic responses to change in % V617F ( molecular response ) in 73 patients with polycythemia vera treated with either interferon ( rIFNa-2b : 28 , Peg-rIFNa-2a : 18 ) or non-interferon drugs ( n = 27 ) , which included hydroxyurea ( n = 8 ) , imatinib ( n = 12 ) , dasatinib ( n = 5 ) , busulfan ( n = 1 ) , and radioactive phosphorus ( n = 1 ) ."
}
